8-K: Profound Medical Expands to Saudi Arabia with Key Deal

Profound Medical Corp. has signed an exclusive distribution agreement with Al Faisaliah Medical Systems Co. to bring its TULSA-PRO and Sonalleve technologies to Saudi Arabia.

Summary

• Profound Medical Corp. entered into an exclusive distribution and supply agreement with Al Faisaliah Medical Systems Co. (FMS) for its TULSA-PRO and Sonalleve technologies in Saudi Arabia.
• FMS is a subsidiary of Al Faisaliah Group, a prominent business conglomerate in Saudi Arabia, and a leading medical device distributor.
• The agreement aims to penetrate Saudi Arabia, identified as the largest healthcare market in the Middle East, with Profound's incision-free and radiation-free therapies.
• All necessary regulatory approvals for importing and selling TULSA-PRO and Sonalleve in Saudi Arabia are already secured.
• TULSA-PRO is an AI-powered, MRI-guided therapy for prostate disease, with over 4,000 men treated and 67 systems installed as of October 2025.
• Sonalleve, also MRI-guided focused ultrasound, is used for conditions like uterine fibroids and adenomyosis, with 10 devices operational and over 4,000 women treated. It is also being researched for pancreatic cancer and other oncological diseases, supported by approximately $10 million in research grants over the last five years.

Sentiment

Score: 8

Explanation: The filing announces a significant exclusive distribution agreement in a major new market with regulatory approvals already in place, indicating strong positive momentum for international expansion and revenue growth potential. The established reimbursement codes for TULSA-PRO in the U.S. further de-risk the core product.

Positives

• Secured an exclusive distribution agreement with a prominent partner, Al Faisaliah Medical Systems Co., for the Saudi Arabian market.
• Entry into Saudi Arabia, described as the largest healthcare market in the Middle East, provides a significant growth runway.
• All required regulatory approvals for TULSA-PRO and Sonalleve in Saudi Arabia are already in place, facilitating immediate market entry.
• The partnership leverages FMS's deep understanding of regional market dynamics and proven track record in introducing advanced medical technologies.
• Expansion of the commercialization strategy beyond North America through strategic distribution partners.
• TULSA-PRO has a growing installed base of 67 systems as of October 2025 and has treated over 4,000 men.
• Sonalleve has treated over 4,000 women and is gaining increasing commercial interest and research funding (approximately $10 million over five years) for new applications like pancreatic cancer.
• The TULSA Procedure received CPT Category 1 codes effective January 1, 2025, establishing reimbursement at Urology Level 7 Ambulatory Payment Classification (APC) in the U.S.

Risks

• Risks inherent in the medical device industry.
• Uncertainties regarding regulatory approvals in other markets.
• Challenges related to reimbursement policies.
• Impact of general economic factors.
• Fluctuations in equity markets.
• Risks associated with growth and competition in the medical device sector.
• Actual actions, events, or results could differ materially from forward-looking statements.

Future Outlook

Profound Medical expects continued commercialization success for TULSA-PRO in the U.S. through its direct sales team and anticipates growth in international markets for both TULSA-PRO and Sonalleve through strategic distribution partnerships. The company foresees the TULSA Procedure becoming a mainstream treatment for the entire prostate disease spectrum and is exploring additional treatment markets for Sonalleve, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Management Comments

• "We're honored to partner for the distribution of both TULSA-PRO and Sonalleve with FMS, one of the leading medical device distributors in the Kingdom of Saudi Arabia." Arun Menawat, Profound's CEO and Chairman.
• "Successfully marketing and distributing our incision-free therapies for the ablation of diseased tissue requires a deep understanding of regional market dynamics and the specific needs of local clinicians and patients." Arun Menawat, Profound's CEO and Chairman.
• "With its proven track record in introducing advanced oncological procedures and other medical technologies in the Kingdom, we're confident that FMS is the ideal partner for us." Arun Menawat, Profound's CEO and Chairman.
• "As Saudi Arabia moves toward economic diversification under Vision 2030, both FMS and our parent company, AFG, are committed to playing a crucial role in shaping the country's future." Mr. Abdullah Al Melik, FMS GM.
• "With our partnership with Profound, we're extremely excited to bring its unique, incisionand radiation-free ablative technologies to Saudi hospitals and treatment centers that aim to be worldwide leaders in patient outcomes." Mr. Abdullah Al Melik, FMS GM.

Industry Context

This agreement positions Profound Medical to capitalize on the growing healthcare market in the Middle East, specifically Saudi Arabia, which is undergoing economic diversification under Vision 2030. The move aligns with a broader trend of medical device companies seeking international expansion, particularly in regions with increasing healthcare infrastructure investment and demand for advanced, minimally invasive treatments. The focus on AI-powered, MRI-guided, incision-free therapies for conditions like prostate disease and uterine fibroids reflects the industry's shift towards less invasive, more precise, and patient-friendly treatment modalities.

Comparison to Industry Standards

• The TULSA Procedure, with its MRI-guided, incision-free, and radiation-free approach, offers a distinct alternative to traditional surgeries or radiation for prostate disease, aiming to preserve urinary continence and sexual function. This positions it favorably against more invasive standard treatments.
• Sonalleve's application for uterine fibroids and adenomyosis, demonstrating pain and symptom relief without affecting ovarian reserve and preserving fertility, provides a non-invasive option that compares favorably to surgical interventions like hysterectomy or myomectomy, especially for women desiring fertility preservation.
• The company's strategy of direct sales in North America and strategic partnerships internationally is a common model for medical device companies expanding globally, leveraging local expertise for market penetration.

Stakeholder Impact

• Shareholders: Potential for increased revenue and market share due to expansion into a new, large market, potentially leading to increased shareholder value.
• Customers (Hospitals/Clinicians): Access to advanced, incision-free, and radiation-free medical technologies (TULSA-PRO and Sonalleve) for treating prostate disease, uterine fibroids, and other conditions in Saudi Arabia.
• Patients: Availability of less invasive treatment options with potential for better outcomes, reduced pain, and quicker recovery for prostate disease, uterine fibroids, and other conditions in Saudi Arabia.
• Employees: Potential for growth and expansion of the company, possibly leading to new opportunities.
• Suppliers: Potential for increased demand for components and services related to TULSA-PRO and Sonalleve systems.

Next Steps

• Profound Medical will continue its direct sales efforts for TULSA-PRO in North America.
• FMS will commence marketing and distribution of TULSA-PRO and Sonalleve in Saudi Arabia.
• Ongoing clinical research for Sonalleve in new applications like pancreatic cancer and other oncological diseases.
• Further exploration of additional potential treatment markets for Sonalleve.

Key Dates

Recommendation

The exclusive distribution agreement with a strong partner in the largest Middle Eastern healthcare market, coupled with existing regulatory approvals, represents a significant de-risked growth catalyst. The established U.S. reimbursement for TULSA-PRO and the ongoing expansion of Sonalleve's applications further strengthen the company's commercial prospects. This strategic move opens a substantial new revenue stream and validates the global appeal of Profound's innovative technologies, making it a compelling investment opportunity.

Keywords

Profound Medical, TULSA-PRO, Sonalleve, Saudi Arabia, Al Faisaliah Medical Systems, Medical Device, Distribution Agreement, MRI-guided therapy, Prostate Cancer, Benign Prostatic Hyperplasia, Uterine Fibroids, Adenomyosis, Focused Ultrasound, Ablation, Healthcare Market, Middle East, Oncology, AI-powered therapy